JENKINTOWN, Pa., Aug. 14, 2023 (GLOBE NEWSWIRE) — SFA Therapeutics, a clinical-stage biotech using a first-in-class immuno-modulation technology platform, announced positive results…
Our pipeline includes treatments for Psoriasis, Liver Cancer (Hepatitis B, NASH and HCC), Ophthalmic Diseases, Cytokine Release Syndrome- a side effect in CAR-T, Prevention of Relapse/Recurrence in Leukemias, and other diseases.
Our microbiome-derived drugs are derived from natural substances and enable a new platform to develope treatments which have the potential to treat over 85 chronic inflammatory diseases currently afflicting patients, providing safer treatments than current therapies.
Liver Diseases: Hepatitis B, Steatosis, NASH, NAFLD
Dermatology: Bullous Pemphigus (Rare Autoimmune Disease)
Ophthalmology: Uveitis
Oncology: Liver Cancer, Hepatocellular Carcinoma (HCC), Prevention of Cytokine Storm in CAR T Therapy.
JENKINTOWN, Pa., Aug. 14, 2023 (GLOBE NEWSWIRE) — SFA Therapeutics, a clinical-stage biotech using a first-in-class immuno-modulation technology platform, announced positive results…
Abstract Cancer is a multi-step process that can be viewed as a cellular and immunological shift away from homeostasis in response…
Med Tech Gurus Developing The Next Big Thing Ira Spector Co-Founder & CEO of SFA Therapeutics delivers a master class in innovation and…
